Tonix Pharmaceuticals (TNXP) Competitors

Tonix Pharmaceuticals (NASDAQ:TNXP) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Do insiders and institutionals believe in TNXP or IMCR?

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 0.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 10.4% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more volatility & risk, TNXP or IMCR?

Tonix Pharmaceuticals has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Is TNXP or IMCR more profitable?

Immunocore has a net margin of -5.70% compared to Tonix Pharmaceuticals' net margin of -828.22%. Immunocore's return on equity of -5.40% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-828.22%	-57.93%	-51.04%
Immunocore	-5.70%	-5.40%	-1.93%

Does the media refer more to TNXP or IMCR?

In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than Immunocore. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 3 mentions for Immunocore. Immunocore's average media sentiment score of 1.51 beat Tonix Pharmaceuticals' score of 0.67 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has better valuation & earnings, TNXP or IMCR?

Immunocore has higher revenue and earnings than Tonix Pharmaceuticals. Immunocore is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$10.09M	30.23	-$130.04M	-$39.47	-0.88
Immunocore	$310.20M	5.27	-$51.09M	-$0.40	-81.05

Do analysts recommend TNXP or IMCR?

Tonix Pharmaceuticals presently has a consensus price target of $70.00, indicating a potential upside of 101.29%. Immunocore has a consensus price target of $56.89, indicating a potential upside of 75.47%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Tonix Pharmaceuticals is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immunocore	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

Immunocore beats Tonix Pharmaceuticals on 10 of the 16 factors compared between the two stocks.